Systemic therapies for salivary gland carcinomas: an overview of published clinical trials

• Luan César Silva ^[4] ; Maria Eduarda Pérez-de-Oliveira ^[5] ; Caique Mariano Pedroso ^[5] ; Amanda Almeida Leite ^[5] ; Alan Roger Santos-Silva ^[5] ; Marcio Ajudarte Lopes ^[5] ; Gilberto de Castro Junior ^[1] ; Manoela Domingues Martins ^[2] ; Vivian Petersen Wagner ^[6] ; Luiz Paulo Kowalski ^[7] ; Cristiane Helena Squarize ^[3] ; Rogerio Moraes Castilho ^[3] ; Pablo Agustin Vargas ^[5]
  1. [1] Universidade de São Paulo

     Universidade de São Paulo

     Brasil

     
  2. [2] Universidade Federal do Rio Grande do Sul

     Universidade Federal do Rio Grande do Sul

     Brasil

     
  3. [3] University of Michigan–Ann Arbor

     University of Michigan–Ann Arbor

     City of Ann Arbor, Estados Unidos

     
  4. [4] Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil; Laboratory of Epithelial Biology, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan, USA
  5. [5] Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil
  6. [6] Department of Oral Pathology, School of Clinical Dentistry, The University of Sheffield-UK
  7. [7] Department of Head and Neck Surgery and Otorhinolaryngology, A C Camargo Cancer Center, São Paulo, SP, Brazil

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 29, Nº. 2 (March), 2024
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • There is no consensus about effective systemic therapy for salivary gland carcinomas (sgcs). Our aim was summarized the clinical trials assessing the systemic therapies (ST) on sgcs.

    Electronic searches were carried out through MEDLINE/pubmed, EMBASE, Scopus, Web of Science, and the Cochrane Library databases, and gray literature.

    Seventeen different drugs were evaluated, and the most frequent histological subtype was adenoid cystic carcinoma (n=195, 45.5%). STable disease, observed in 11 ST, achieved the highest rate in adenoid cystic carcinoma treated with sunitinib. The highest complete (11.1%) and partial response (30.5%) rates were seen in androgen receptor-positive tumors treated with leuprorelin acetate.

    Despite all the advances in this field, there is yet no effective evidence-based regimen of ST, with all the clinical trials identified showing low rates of complete and partial responses. Further, translational studies are urgently required to characterize molecular targets and effective ST.